• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
The Genome
CMECNE

Familial vs. Hereditary Disease: Definitions and Key Counseling Points

image_pdfFavoriteLoadingFavorite

Learning Objectives and CME/Disclosure Information

This activity is intended for healthcare providers delivering care to women and their families.

After completing this activity, the participant should be better able to:

1. Describe why reduced penetrance or variable expressivity may complicate a pedigree
2. Discuss the differences between hereditary vs familial disease

Estimated time to complete activity: 0.25 hours

Faculty:

Susan J. Gross, MD, FRCSC, FACOG, FACMG President and CEO, The ObG Project

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.


The PIM planners and others have nothing to disclose. The OBG Project planners and others have nothing to disclose.

Faculty: Susan J. Gross, MD, receives consulting fees from Cradle Genomics, and has financial interest in The ObG Project, Inc.

Planners and Managers: The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP have nothing to disclose.

Method of Participation and Request for Credit

Fees for participating and receiving CME credit for this activity are as posted on The ObG Project website. During the period from 8/30/2021 through 8/30/2023, participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, please complete the test and evaluation. Upon registering and successfully completing the test with a score of 100% and the activity evaluation, your certificate will be made available immediately.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and The ObG Project. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hours.

Read Disclaimer & Fine Print

SUMMARY:

The terms ‘hereditary’ and ‘familial’ are sometimes used interchangeably, but are two different concepts

  • ‘Hereditary’ is most commonly used when referring to diseases with a known genetic cause
  • ’Familial’ disorders are those which appear to have a genetic component, affecting more family members than would be expected by chance alone
    • However, a single genetic cause or explanation is not known

Hereditary Disease

  • Generally single gene disorders can often, but not always, be confirmed by a genetic test
  • Certain genetic diseases can be identified based upon clinical diagnosis alone, without genetic testing or even evaluation of a family history
    • For example, Marfan syndrome (see ‘Learn More – Primary Sources’ below) is an example where a diagnosis can be made based on meeting certain clinical criteria
  • If a genetic cause is found
    • Cascade testing can be helpful, where members who are seemingly unaffected by disease can also be tested to determine if they are at risk for future disease development (see ‘Related ObG Entries’ below)

Familial Disease

  • Usually occurs in more individuals in a family than expected by chance
  • Genetic and environmental factors coupled with family history play a role in determining the individuals’ risk
    • For example: An individual presents with high blood pressure and heart disease with a father who had an MI at age 65 | While there are single gene disorders associated with CVD, in the majority of cases this scenario would be considered familial | Note that other important behavioral factors along with family history would impact risk and outcomes (e.g., sedentary lifestyle and high fat diet)  

Important Concepts that Can Make Differentiating Between Familial and Hereditary Disorders More Challenging

  • Variable expressivity: a single gene disorder may present differently in multiple family members
    • In the case of a pathogenic variant in BRCA1, one woman might develop breast cancer at 45, while her brother develops prostate cancer at 72, even though both siblings carry the same exact mutation
  • Reduced Penetrance: a person is known to carry a genetic mutation (either through a genetic test or they are an obligate carrier of the mutation) but they do not exhibit symptoms of that disease
    • In the case of BRCA1: the father of the children above, carries the pathogenic BRCA1 variant – but he is 85 and never developed cancer

Note: When inheritance patterns are clear cut (e.g. autosomal dominant pattern with multiple affected family members), determining that a disorder is hereditary and likely due a significant pathogenic variant is easier | Unfortunately, variable expressivity and reduced penetrance can complicate the presentation | Genetic expertise can be helpful for pedigree analysis to distinguish between familial and hereditary disease and potential risks  

Differentiating Between Hereditary or Familial Disease

  • Determining whether a disorder is hereditary requires a detailed evaluation of family history
    • Review by a trained genetics professional with careful attention to detail can be helpful
    • Typically includes a three-generation pedigree with ages of diagnoses
  • Genetic testing is an important way to determine if a disease is ‘Hereditary’ or ‘Familial’
    • Known pathogenic variant is identified: Disease considered ‘hereditary’
    • No pathogenic variant identified, yet a strong family history of disease is present: Disease considered ‘familial’ (unless a genetic/hereditary diagnosis can be made based on clinical features alone)

KEY POINTS:

  • Many disorders have an important genetic component, but are not caused by a known inherited change in a particular gene
  • When counseling patients, the following are potential reasons that a disorder can appear to be tracking more frequently within a family but no definitive genetic answer has yet been found
    • The causative gene has not yet been discovered
    • Perhaps numerous genes and environmental factors are leading to the familial risk
    • Perhaps our current technology cannot uncover the genetic mutation underlying the condition
  • Knowing that a condition runs in a family, whether hereditary or familial, can help individuals make proactive lifestyle decisions, in the hopes that it will reduce their risk for disease
    • For example, there are prophylactic surgeries that may be offered women with BRCA pathogenic variants such as risk reducing mastectomy (see ‘Learn More – Primary Sources’ below)
    • Generally, hereditary disorders will carry higher risk for family members and offspring (e.g., carriers of BRCA pathogenic variants vs those with some affected relatives, but no known mutations)
  • It can still be helpful to know if a condition is familial because there may be differences in medical recommendations for the patient and family
    • For example, the Gail Calculator considers family history in assessing a woman’s 5-year and lifetime risk for breast cancer and can inform whether risk reducing medications (e.g., raloxifene) should be offered (see ‘Learn More – Primary Sources’ below)
  • Referral to a genetic counselor can be very helpful to distinguish between familial or hereditary disease

Learn More – Primary Sources:

ACOG: Family History as a Risk Assessment Tool

Children’s Wisconsin: Multifactorial inheritance

Medline Plus: What is Heritability?

Medline Plus: What are Multifactorial Disorders?

Take a post-test and get CME credits

TAKE THE POST TEST

Want to stay on top of key guidelines and research papers?

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All The Genome Posts
Next >

Related ObG Topics:

Cascade Testing: Notifying and Counseling Relatives of Individuals who are BRCA Mutation Carriers
BRCA1 & BRCA2 Mutations: What Are the Risks for Developing Breast and Ovarian Cancer?
What Do You Really Need to Know About Your Patient’s Family History?
Professional Recommendations for Use Pharmacologic Interventions to Reduce Breast Cancer Risk
Prophylactic Mastectomy and BRCA – Risk Reduction and Guidelines
Marfan Syndrome: a Reportable ACMG Secondary Finding

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site